Published in J Allergy Clin Immunol on September 18, 2015
Pioglitazone Therapy for Chronic Granulomatous Disease | NCT03080480
Clearance of apoptotic neutrophils and resolution of inflammation. Immunol Rev (2016) 0.82
PPARγ in Bacterial Infections: A Friend or Foe? PPAR Res (2016) 0.75
Advances in clinical immunology in 2015. J Allergy Clin Immunol (2016) 0.75
The immune response to secondary necrotic cells. Apoptosis (2017) 0.75
Macrophages, inflammation, and insulin resistance. Annu Rev Physiol (2010) 11.77
Chronic granulomatous disease. Clin Rev Allergy Immunol (2010) 2.32
Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J Leukoc Biol (2003) 1.53
ROS-deficient monocytes have aberrant gene expression that correlates with inflammatory disorders of chronic granulomatous disease. Clin Immunol (2008) 1.23
PPARγ activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease. Blood (2010) 1.18
Involvement of a functional NADPH oxidase in neutrophils and macrophages during programmed cell clearance: implications for chronic granulomatous disease. Am J Physiol Cell Physiol (2009) 1.16
The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: From physiology to pathology. J Allergy Clin Immunol (2013) 1.15
PPARγ in Inflammatory Bowel Disease. PPAR Res (2012) 0.96
Pioglitazone restores phagocyte mitochondrial oxidants and bactericidal capacity in chronic granulomatous disease. J Allergy Clin Immunol (2014) 0.94
An efferocytosis-induced, IL-4-dependent macrophage-iNKT cell circuit suppresses sterile inflammation and is defective in murine CGD. Blood (2013) 0.92